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ABSTRACT
Objectives: To explore the acceptability of pre-exposure
prophylaxis (PrEP) among gay, bisexual and men who
have sex with men (MSM) and migrant African
communities in Scotland, UK.
Design: Consecutive mixed qualitative methods
consisting of focus groups (FGs) and in-depth interviews
(IDIs) explored PrEP acceptability. Data were digitally
recorded, transcribed and analysed thematically to identify
anticipated and emerging themes.
Setting: Participants were recruited through community
sexual health and outreach support services, and from
non-sexual health settings across Scotland.
Participants: Inclusion criteria included identification as
either MSM and/or from migrant African communities;
18 years and older; living in Scotland at the time of
participation. 7 FGs were conducted (n=33): 5 with MSM
(n=22) and 2 mixed-sex groups with African participants
(n=11, women=8), aged 18–75 years. 34 IDIs were
conducted with MSM (n=20) and African participants
(n=14, women=10), aged 19–60 years. The sample
included participants who were HIV-positive and
HIV-negative or untested (HIV-positive FG participants,
n=22; HIV-positive IDI participants, n=17).
Results: Understandings of PrEP effectiveness and
concerns about maintaining regular adherence were
identified as barriers to potential PrEP uptake and use.
Low perception of HIV risk due to existing risk
management strategies meant few participants saw
themselves as PrEP candidates. Participants identified risk
of other sexually transmitted infections and pregnancy as
a concern which PrEP did not address for either
themselves or their sexual partners. PrEP emerged as a
contentious issue because of the potentially negative
implications it had for HIV prevention. Many participants
viewed PrEP as problematic because they perceived that
others would stop using condoms if PrEP was to become
available.
Conclusions: PrEP implementation needs to identify
appropriate communication methods in the context of
diverse HIV literacy; address risk-reduction concerns and;
demonstrate how PrEP can be part of a safe and
comprehensive risk management strategy.
Pre-exposure prophylaxis (PrEP) represents a
significant biomedical addition to inter-
national HIV prevention efforts. The clinical
efficacy of the use of antiretrovirals (ARVs)
by HIV-negative individuals to prevent the
sexual transmission of HIV has been exten-
sively reported.1 2 The acceptability of PrEP
to potential PrEP users (or candidates) to
date has focused largely, although not exclu-
sively, on the risk of inefficient PrEP use,
such as low or inconsistent adherence to the
medication and reduced condom use. It has
also focused predominately on experiences
in the USA.3–5 There are currently a number
of PrEP demonstration studies underway in
the UK, Australia, the USA and elsewhere to
explore how it might be used in ‘real world’
settings.6 7 Despite being available in the
USA since the Food and Drug
Administration (FDA) approved truvada
(emtricitabine/tenofovir disoproxil fumar-
ate) for use as PrEP in 2012, there has been
Strengths and limitations of this study
▪ Our study offers new insights into the psycho-
logical and social barriers to pre-exposure
prophylaxis (PrEP) uptake and use.
▪ This paper identifies how limited understandings
of PrEP effectiveness and wider community atti-
tudes affect PrEP acceptability.
▪ We demonstrate the need to consider socially
embedded sexual risk management strategies,
which address concerns beyond the risk of HIV
transmission.
▪ We suggest there is a need to consider how clin-
ical research is translated into real world con-
texts and communicated to potential users, as
well as how potential users are supported in
integrating this information into existing risk
management strategies.
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relatively low uptake among targeted communities
affected by HIV, including gay, bisexual and other men
who have sex with men (MSM).6 Moreover, PrEP has
emerged as a controversial issue among those affected
by HIV8 9 and there are clear global inequalities in
terms of access to PrEP as it is still only available off-label
in a number of countries.
There is a need to understand how uptake and use of
PrEP as an HIV prevention strategy could be affected by
a range of factors, such as community attitudes towards
PrEP and the role of PrEP within concurrent HIV pre-
vention strategies of potential PrEP users.10 11 We report
on the first qualitative study in the UK of the acceptabil-
ity of PrEP among populations most affected by HIV to
inform targeted PrEP implementation strategies.
METHODS
This article describes a mixed qualitative methods study
on the acceptability of PrEP and treatment as prevention
(TasP) with two communities in Scotland: (1) MSM and
(2) men and women from migrant African communities
(first generation immigrants including asylum seekers,
students and other migrants). HIV is largely concen-
trated in these two communities in the UK, as they rep-
resent the highest levels of HIV prevalence.12 13 This
article reports on findings in relation to barriers to PrEP
use. Our sample included HIV-negative and/or untested
participants as potential PrEP users and HIV-positive
participants as the potential or existing sexual partners
of PrEP users. We include findings from HIV-positive
participants because of evidence which indicates that
serodiscordant sexual partnerships may be an important
factor in PrEP acceptability.14 HIV-positive individuals
may shape PrEP uptake through influence on commu-
nity attitudes, as well as more directly on potential
HIV-negative sexual partners.
First, exploratory focus groups (FGs) were conducted
with a convenience sample of MSM and African partici-
pants between August and November 2012 to identify
community attitudes and emerging issues around PrEP
acceptability. We conducted seven FGs: five with MSM
(n=22), and two mixed sex groups with African partici-
pants (n=11). Three FGs were conducted with
HIV-positive MSM (n=14) and one FG with HIV-positive
Africans (n=8). Participant age ranged between 18 and
75 years and discussions took place in urban and semiur-
ban locations across central Scotland. Participants were
recruited through existing community and/or support
groups with the assistance of sexual health and/or
LGBT (lesbian, gay, bisexual and transgender) organisa-
tions. FG discussion topics included existing risk man-
agement strategies in sexual health and an exploration
of PrEP and TasP (see box 1).
We then conducted 34 in-depth interviews (IDIs)
between March and September 2013 with a purposive
sample of MSM (n=20) and African participants (n=14)
to explore issues emerging from FG findings and
examine personal risk management practices in further
depth. Half of the IDI participants were HIV negative or
untested for HIV, and the other half had been diag-
nosed with HIV at the time of the interview (MSM,
n=10; Africans, n=7). Inclusion criteria did not specify
risk behaviour to allow for broad exploration of candi-
dacy factors, including those not related to sexual behav-
iour. IDI participants were aged 19–60 years and were
resident in four Scottish regions (Glasgow, Lothian,
Lanarkshire and Grampian). Tailored flyers and posters
were distributed to: workshops and support groups; com-
munity sexual health testing clinics; gay bars, saunas and
clubs; an MSM mail-out condom programme; commer-
cial venues (eg, African food and barber shops) and in
educational settings known to have large African student
populations. Community organisations also made
contact with potential participants through their regular
online and face-to-face outreach and support work.
Interviews took place in private spaces, in partner orga-
nisations or in participants’ own homes, and focused the
acceptability of PrEP and TasP, including awareness,
potential use, concerns and combination with other
and/or existing risk management strategies (such as
TasP, serosorting, etc) (see box 2).
PrEP was explained to participants by drawing on but
not limited to the use of a visual aid (figure 1). Basic
explanations of PrEP were consistent across all FG and
IDI discussions (box 2, section 4a). Subsequent and
more detailed descriptions of PrEP varied depending on
participant questions, which were encouraged and
answered. This approach was taken to identify how PrEP
should be described to potential candidates. Material
did not specify an exact efficacy rate due to the emer-
ging clinical data, variability according to adherence,
Box 1 Focus group discussion guide
Part 1
Participants were presented with a number of objects to discuss.
Objects included: condoms, sachets of lubricant, pregnancy test,
list of antiretrovirals, mocked up bottle of antibiotics, empty
boxes/bottles of truvada, and pictures of: an Oraquick® In-Home
HIV Test and rapid HIV tests.
▸ What do these objects make you think about?
▸ How do these objects relate to risk and HIV?
▸ What is risky in relation to HIV?
▸ Do you use these objects to manage HIV?
▸ What else do you use to manage HIV?
Part 2
Provide visual cards of pre-exposure prophylaxis and treatment as
prevention provided and explain separately.
▸ How might you use these pills?
▸ How do you think your friends or sexual partners might use
these pills?
▸ Are you concerned about the use of pills as a form of HIV
prevention?
▸ Would these pills change the way people currently manage
HIV? What do you think about this?
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Box 2 Interview topic guide for HIV-negative or untested participants
1. Experiences with and/or proximity to HIV
▸ Is HIV a risk for you?
▸ Is HIV something that you talk about with your sexual partners? (or friends?)
▸ Have you ever tested for HIV?
2. Risk management/sexual health
▸ What are the risks for you in relation to sexual health?
▸ You’ve said that you manage risk in sexual health by…Has this changed and how?
▸ Do you talk to your sexual partners about how you manage your sexual health?
▸ Do you use health or other services to help you manage your sexual health? If so, how?
3. Use of existing technologies
▸ List of sexual health technologies physically presented to participant:
– Condoms
– HIV testing
– Sexually transmitted infections (STIs) testing
– Contraception (the pill, intrauterine devices, long-term injections, etc)
– Pregnancy testing
– CD4 counts
– Viral loads
– Antiretrovirals (ARVs)
– Postexposure prophylaxis (PEP)
▸ Do you use any of these now? Have you used any of these in the past?
▸ How have you used them? What made you use them?
▸ Have you used any of these in combination with other prevention methods?
▸ How do you feel about using them?
▸ If you started/stopped using some of these, can you say why you did?
4. Potential use of new technologies
A. Pre-exposure prophylaxis (PrEP)
▸ Approximate PrEP description explained to participant:
PrEP is when ARVs are used by people who are HIV negative to prevent the transmission of HIV. At the moment, it can be taken once
a day, although researchers are looking into other forms (short-term PrEP, long-acting injectable, topical gel/microbicides). PrEP only
works if people take the medication regularly. Clinical trials have shown that it is effective in relation to how often people take the pills.
People are still encouraged to use condoms and other forms of risk reduction with PrEP use. There are some side effects, but this
may not affect everyone and it generally seems to be well tolerated in the clinical trials. PrEP is not currently available in the UK, but it
has been licenced for use in the USA.
▸ Have you heard of PrEP before?
▸ What do you think of PrEP as a prevention method?
▸ How would you feel about using PrEP as a prevention method?
▸ If you would use PrEP, how do you think you would you use it?
▸ Do you have any concerns about PrEP as a prevention method?
▸ Do you think other people might use PrEP as a method?
B. Treatment as prevention (TasP)
▸ Approximate TasP description explained to participant:
TasP is when ARVs are used by people living with HIV not only to clinically manage HIV, but also to help prevent the transmission of
HIV. TasP manages the ‘viral load’ or the amount of HIV in the system. Research has shown that having an ‘undetectable’ viral load
means that transmission of HIV is unlikely to happen. So, if the HIV positive person is taking their treatment regularly, and they do not
have an STI, and their viral load is ‘undetectable’ for a period of time (about 6 months), they would clinically be considered not infec-
tious. TasP in particular is when treatment is started to prevent transmission, rather than when the person clinically needs the treat-
ment. If someone starts this treatment early—including for prevention reasons—they cannot stop taking this medication. So although
people living with HIV will eventually move onto treatment, perhaps after 5 to even 10 years, this would mean starting treatment con-
siderably earlier.
▸ Have you heard of TasP before?
▸ What do you think of TasP as a prevention method?
▸ Can you imagine using this as a prevention method with a sexual partner who is HIV positive?
▸ How would you feel if a sexual partner suggested this as an HIV prevention method?
▸ Do you have any concerns about this as a prevention method?
▸ How do you think other people who are HIV negative or untested might feel about using ARVs or HIV treatment as a prevention
method?
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and to not overly complicate the explanation.
Participants were informed that PrEP efficacy was
dependent on levels of adherence, as demonstrated in a
number of trials. FG participants were told that the
iPrEx study reported approximately 73% protection if
taken regularly (90% adherence), which was accurate at
the time discussions were conducted.15 IDI participants
were informed that efficacy could be up to or more than
90% if taken regularly, drawing on subsequent sub-
analyses of clinical findings.2 Participants were informed
that other forms of risk reduction were recommended,
such as condoms.16 Efficacy of condoms was described
as less than 100%.17 18 Discussions explored a wide-
range of PrEP scenarios, including non-condom use.
Written consent was provided by all participants at the
start of the FGs and IDIs. All FGs and IDIs were digitally
recorded and transcribed verbatim. Transcripts were
anonymised and coded in NVivo V.10. Data were ana-
lysed thematically, drawing on anticipated as well as
emergent themes.19–21 Rigour throughout the analysis
was achieved through an iterative process of discussion
and revision between coauthors.19 20 22
RESULTS
We identified five potential barriers to effective PrEP use:
interpreting effectiveness; managing adherence; PrEP candi-
dacy and low perceptions of HIV risk; concerns with other
risks such as the criminalisation of HIV transmission and
sexually transmitted infections (STIs); and moral barriers.
We have identified extracts taken from FGs; otherwise, it can
be assumed that the extract comes from an IDI participant.
Interpreting effectiveness
Understandings of PrEP effectiveness emerged as an
important barrier to potential and effective use. Although
participants were informed that PrEP was highly effective
when taken regularly, most participants expressed con-
cerns that it provided less than 100% protection and there-
fore was ‘insufficient’ to prevent HIV transmission on its
own. Some participants felt that PrEP used in isolation was
‘too much’ of a risk (if only approximately 70% effective).
Respondent 1: That’s not enough, that’s not enough,
exactly.
Respondent 2: Its seventy-two per cent effective but then
there’s still that twenty-eight per cent. (HIV-negative
MSM, FG)
Participants also expressed a wider scepticism of PrEP,
which emerged in two ways. Some thought that the
advice to use condoms with PrEP indicated a continued
scientific uncertainty: “I don’t know if this [will] work
because since they said if you use it you can still use
condom, that means they are not sure as well”
(HIV-negative African woman). Second, some expressed
scepticism in relation to the variability in reported effi-
cacy rates in relation to adherence. As a result, there was
a reluctance to trust these, unless the information came
from a recognised, trusted and reliable source.
R1: There’s so much out there right, on the internet an’
everything else right, if it came up on the news right?
The logistic news on BBC one that this pill will prevent
so…—like a hundred per cent—that’s when I would
believe it would work. I [would not] trust any other pill…
Question: So it has to be a hundred per cent?
R2: ‘cause there’s a lot a…no like—anyone can put some-
thing on the internet, …You’ve got to use like certain
websites, you’ve got to look like .org, .gov, those type o’
websites. You’ve just done one that’s like www.medicine.
co.uk it’s not a…it’s not like a legitimate website it could
just be anyone postin’ stuff up there.
Q: Well I suppose in the States it’s from the Food and
Drug Administration so it’s got that stamp on it.
R1: Yes, but you [don’t know] if they’re been a hundred
per cent accurate on their job or just been lazy an’ the
fact that we’re brave enough to take it to human trials
right? (HIV-negative MSM, FG)
In spite of being told that the FDA had approved the
drug, these FG participants did not recognise the organ-
isation or trust it as a reliable source, and were therefore
sceptical about its statements and/or endorsement.
Figure 1 Pre-exposure prophylaxis (PrEP) Visual Aid.
ARVs, antiretrovirals.
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Other participants were less concerned about PrEP
not being 100% efficacious because they imagined that
it would be used in addition to condoms. However, parti-
cipants expressed confusion or uncertainty in knowing
how to interpret efficacy rates and their impact on risk
reduction in this particular context. For example, in dis-
cussing the effectiveness of condoms in relation to other
prevention strategies, one participant calculated the pro-
tection offered by PrEP, condoms and TasP with a hypo-
thetical HIV-positive sexual partner. Assuming that PrEP
was 90% effective at reducing HIV transmission, he
explained:
R: but there’s obviously still a 10% risk but, as you said,
there’s the same risk with condoms. So it’s either you
take the 10% risk or you say ‘well, I’ll use condoms and
we’ll use TASP’ which makes 180%. (Laugh)
Q: And PrEP. (Laugh)
R: 253 out of 300! (HIV-negative MSM)
Although the participant in this extract was joking
about adding up the numbers, the interpretation of effi-
cacy rates in relation to other prevention options posed
a potential source of confusion or misinformation for
participants.
Managing adherence
Given the evidence concerning the patterning of effi-
cacy by adherence,2 maintaining regular adherence to
medication was identified as a potential barrier to effect-
ive PrEP use. Some participants described how they
might forget to take tablets or their routine might be
disrupted because of non-regular working patterns, and
were therefore concerned about how effective PrEP
would be if they did not take the drugs regularly:
“Sometimes I forget. Because I don’t have a regular
sleeping pattern, so sometimes I’ll fall asleep at four in
the afternoon and I usually take my pills [for an existing
health condition] after dinner” (HIV-negative MSM).
Establishing and maintaining a routine to take PrEP was
also affected by the perception of social stigma attached
to HIV medication. This meant maintaining daily adher-
ence would be difficult if there was limited privacy
(eg, the presence of roommates) or if there was a
change in environment. One participant reported con-
cerns about his family potentially finding the tablets:
If I was on those medications for a year and if I went
home…or anything like that I’d find it very difficult to be
able to take my medications or I would find it a bit of a
barrier that if my family knew about it they’d investigate
why are you on these pills. And again that would prob-
ably put some doubt in their head and then they’d prob-
ably then think the worst—that I was HIV positive.
(HIV-negative MSM)
In addition to being unable to establish or maintain a
regular routine to facilitate good adherence, most
participants expressed concerns about the physical
effects of the drugs themselves, and how the side-effects
might inhibit taking them. Some participants described
disliking taking tablets and that this would be a barrier
to daily PrEP use: “I don’t really like pills so I don’t
think I would take any pills every day” (HIV-negative
African man). Many viewed the potential for side-effects,
such as nausea and diarrhoea, as too great a trade-off
for increased HIV prevention, in spite of being informed
that trials had reported high tolerance of the drugs:
But, could I put up wi’ side-effects all the time as well,
like taking a pill, and going tae a nightclub, and ended
up wi’ diarrhoea? You know, you’ve gotta think of things
like that, am I [going to] take this? Am I [going to]
stand tired, have a headache in a club just at the fact that
I might at the end of it get a shag…(HIV-negative MSM)
Other participants felt the side-effects would interfere
with sexual practice itself: “Nausea, an’ diarrhoea an’—
you’ll be shittin’ all over his [penis]. No [thanks].”
(HIV-negative MSM, FG). A large minority of
HIV-positive as well as HIV-negative participants raised
the issue of longer term side-effects, especially those
who were more familiar with the effects of ARVs:
Does it not have any side effects inside my body? ‘Cause
from my reading as well, some of these anti-retrovirals
have got side-effects with the lungs, with the kidneys and
stuff. So, in the long run, if I get used to drinking this
pill and I’m actually not exposed because I’m thinking I
might be at risk of getting exposed, am I not doing more
damage to myself in my body? (HIV-negative African
woman)
PrEP candidacy and low perceptions of HIV risk
Many participants described scepticism in taking PrEP
daily, especially if they were not always exposed to or at
risk of HIV transmission. As such, perceptions of HIV
transmission risk played an important role in potential
uptake of PrEP. Several participants rejected the use of
PrEP because they perceived themselves to be at a very
low risk. For the majority of HIV-negative participants,
this was because most adopted serosorting or believed
they could accurately tell if a potential partner was HIV
positive and avoid sex with him or her: “I wouldn’t just
[want to] take a risk because it’s already defining as a
risk, I mean, it’s a risk, it’s already been defined as a risk
and since I’m a little bit risk averse…I won’t just do any-
thing” (HIV-negative African man). HIV stigma and
assumptions about disclosure appeared to inform these
strategies. For example, some HIV-negative participants
assumed that HIV-disclosure to sexual partners “was the
law” (HIV-negative MSM, FG), and that their sexual part-
ners were not HIV positive. Those HIV-negative partici-
pants in serodiscordant relationships and HIV-positive
participants suggested that condoms, and the nature of
their relationships (eg, monogamous), already helped
manage their risks, and that the additional benefit from
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PrEP was unnecessary. One man in a serodiscordant
relationship explained:
Right now in my current situation as, I’m doing a monog-
amous relationship and everything like that, again I don’t
think even in that [instance] I don’t think I would take
the pills even though it would be an extra measure…I
think I would feel comfortable enough in the current
situation. (HIV-negative MSM)
PrEP and concerns with other risks
Both HIV-positive and HIV-negative participants identi-
fied risk of other STIs as a concern for themselves and
their sexual partners. Heterosexual African participants,
especially African women, also talked of the risk of preg-
nancy. For those participants who were either living with
HIV, or who had experience of serodiscordant relation-
ships, other health risks posed to the HIV-positive sexual
partner through PrEP use were also identified:
when I’m looking at condom use it’s not just HIV that
you’re protecting yourself against but some other STIs as
well. So you’re killing two birds with one stone, more like
it. But when it’s now using this, you’re actually getting
yourself involved in something that you already know
—‘this person is positive and I’m [going to] have sex
with him, but it’s okay, I will not use condoms because I
know I can use this.’ But you’re also putting that person,
because that person’s immune system might be weak.
They’re also putting that person at risk of other STIs as
well, instead of using condoms. So I think it makes
people more ignorant of the other things as well. And it
makes people just more focused on just HIV and not
other STIs. And then risk of pregnancy as well is likely to
get high, provided the people are not on any other form
of contraception….No, I think…no, from the way you’ve
said it to me…I wouldn’t even tell it to people.
(HIV-negative African woman)
Most HIV-positive participants described anxieties
about PrEP in relation to their inability to be in effective
control of HIV prevention. One woman could not
imagine agreeing to her HIV-negative sexual partner
using PrEP: “[PrEP] is too risky for him because I don’t
know when he stop using it, what will happen to him”
(HIV-positive African woman, FG).
Moral barriers to PrEP
PrEP emerged as a highly contentious issue because of
the perceived negative implications it had for existing
risk management strategies and HIV prevention. Many
participants viewed PrEP as problematic because they
perceived that others would stop using condoms if PrEP
was available. That is, they distinguished between how
they might use PrEP and how they perceived others
would use it. For some, the concern was in relation to
reduced condom use: “it’ll be like…women burning
their bras. It’ll be all these guys [whipping] off their
condoms, do you know what I mean?” (HIV-negative
MSM). Other participants were also concerned with
bigger changes in sexual practice, such as increased risk
taking:
Are you trying to eliminate the condom?…There is no
place for a condom at all when it’s like this. So I think it
actually encourages people to be more promisc…not pro-
miscuous, but to be more…I don’t know [if] ‘ignorant’ is
the right word, but to be less careful ‘cause they know
‘oh, there’s that pill’. And it’s not even cost-effective than
just getting a condom or using…PEP once in a blue
moon. (HIV-negative African woman)
Not all participants were opposed to PrEP and many
viewed PrEP as a good addition to HIV prevention
options. However, there was still concern about how
PrEP would be accessed. Overall it was hoped that it
would be made available only under strict conditions to
ensure the ‘right’ people received it and that it was used
in the ‘correct’ way:
I believe it should be available in Scotland. But, it should
be under strict control to make sure the person who
takes it knows that he, or she is not protected to full
extent from other infections, and HIV either.
(HIV-negative MSM)
DISCUSSION
This is the first qualitative study in the UK to report on
the acceptability of PrEP. Our research offers new
insights into the psychological and social barriers to
PrEP uptake and use. We identified the significance of
how the effectiveness of PrEP as a risk-reduction inter-
vention is communicated to and understood by potential
candidates. Our research suggests the importance of
HIV risk perception and found that, for many partici-
pants, PrEP was not immediately seen as a trusted and/
or beneficial addition to their repertoire of existing
risk-reduction practices. Our findings also highlight how
existing risk management strategies in relation to PrEP
encompass broad concerns relating to sexual health,
relationships, social factors and communities.
Understanding how to interpret PrEP efficacy rates,
on their own and in combination with other prevention
strategies, proved a stumbling block for the participants
and poses a considerable challenge to how health provi-
ders support the concept of combination prevention in
the context of PrEP. Liu et al23 identify accurate con-
sumer knowledge as key to PrEP implementation, in
addition to addressing other factors such as stigma,
adherence and risk reduction. While we agree with Liu,
our findings suggest that the form and delivery of this
consumer knowledge, including how health providers
understand and communicate this information, needs
further attention to support effective PrEP use.
Communicating PrEP effectiveness in real world settings
will be a two-way process that demands clarity on the
part of providers and potential users. In addition to sup-
porting providers, negotiating PrEP as a prevention strat-
egy will require improved levels of HIV literacy among
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potential PrEP users to be effective. We suggest the need
to consider critical HIV literacy, which encompasses the
ability to know, understand and use HIV-related informa-
tion within existing risk-reduction practices.24 As levels
of HIV knowledge are directly affected by a range of
factors, such as proximity to HIV,25 inequalities in HIV
literacy within communities affected by HIV will play an
important role in understanding the barriers to PrEP
use. These factors have direct implications for both the
nature of how PrEP-related HIV risk prevention is deliv-
ered and by whom.
For many participants, PrEP was not seen as a neces-
sary or welcome addition to their repertoire of risk man-
agement strategies. Our findings suggest that risk
perception and candidacy will play a critical role in deci-
sions to use PrEP, a finding echoed by Golub et al.26 For
some of the HIV-negative and/or untested participants
in our study, the rejection of PrEP as unnecessary
emerged from a perception that they were not at risk of
HIV transmission. HIV risk was managed often through
the sexual exclusion of HIV-positive sexual partners or
through reliance on monogamous sexual relationships.
These findings suggest that PrEP implementation strat-
egies will need to engage with these wider, socially
embedded risk-reduction practices, including how HIV
stigma might affect risk perception. Moreover, our
research highlights how the management of risk was not
limited only to HIV transmission, but also to the risk of
STIs, pregnancy and social stigma. Participants described
how PrEP would not adequately address these existing
risks, and even had the potential to create significant
new risks. Saberi et al27 reported similar moral concerns
about the implications of PrEP on condom use in their
study with MSM participants in serodiscordant relation-
ships in the USA. Although they surmise that proximity
to HIV and age play a role in these concerns, our find-
ings suggest that moral objections to PrEP were not
limited by age or sexuality. We suggest that these moral
reactions to PrEP as a risk-reduction option are related
to broader social and community concerns about the
potential for PrEP to radically change the way preven-
tion is practiced.9 This highlights the need to engage
with wider social concerns about what constitutes
‘inappropriate’ or high-risk sexual practice in relation to
PrEP and to demonstrate how PrEP implementation can
be a part of a safe and comprehensive risk management
strategy.
Our study has a number of strengths and limitations.
We employed rigorous qualitative methodology which
enabled in-depth exploration of the social meanings of
PrEP acceptability and likely use.21 We therefore add to
the existing quantitative PrEP acceptability research.
With a small sample of MSM and migrant African parti-
cipants in a non-generalised HIV epidemic, some of
whom were engaged in sexual health or community ser-
vices, our findings are not generalisable to a wider popu-
lation but we would argue, are transferable to similar
populations in similar social contexts. As we did not
sample according to sexual risk behaviour, our findings
are only transferrable to broad risk groups and not
necessarily to ‘high risk’ individuals. Our inclusion of
the recommendation to use condoms in the visual PrEP
information may have biased the findings. However, our
discussions included consistent and broad descriptions
of PrEP and encompassed a wide range of PrEP scen-
arios, including non-condom use.
Our research identifies the need to consider acceptabil-
ity factors which extend beyond drug adherence and risk
compensation when introducing and scaling up PrEP and
has a number of implications for policy and clinical prac-
tice. In particular, it will be necessary to develop clear tools
and techniques to communicate PrEP information to
potential candidates, and to support health providers in
the implementation of these tools. These methods will
need to translate clinical research relating to PrEP effective-
ness in real world contexts as is appropriate in the context
of diverse critical literacy skills. Implementation will also
need to address low-risk perception, non-HIV-related risk
reduction and other moral concerns to demonstrate how
PrEP can be a part of a safe and comprehensive risk man-
agement strategy. Our study suggests that broader social
and community concerns about the potential for PrEP to
change HIV prevention need to be addressed by support-
ing the integration of PrEP into existing risk management
strategies and through targeted promotion.
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